CLINICAL EFFICIENCY AND THE PHARMACOECONOMIC ANALYSIS OF ALLERGEN IMMUNOTHERAPY AT PATIENTS WITH MILD AND MODERATE ALLERGIC BRONCHIAL ASTHMA

Purpose: an assessment of clinical efficiency and carrying out the pharmacoeconomic analysis of allergen immunotherapy at patients with mild and moderate allergic bronchial asthma.

Materials and methods. 108 patients were examined with mild and moderate allergic bronchial asthma, of both sexes who were divided into 4 groups depending on their therapy. The period of observation was 12 months. The 1st group were included 35 patients of mild allergic bronchial asthma receiving allergen immunotherapy in combination with antiinflammatory therapy; the 2nd group were consisted of 22 patients of mild allergic bronchial asthma using only basic therapy; in the 3rd group 17 patients of moderate allergic bronchial asthma receiving allergen immunotherapy in combination with antiinflammatory medicine were observed; the 4th group was made by 34 patients of moderate allergic bronchial asthma receiving only basic therapy. At all patient were investigated the function of external respiration, scarification tests, test АСТтм. For the pharmacoeconomic analysis we used the cost-effectiveness ratio.

Results. Our analysis showed that the scheme of treatment at patients of the 3rd group was economically more profitable in comparison with the scheme of treatment at patients of the 4th group. So at the 3rd group in the end of the period of observation was noted significant improvement of the following indicators: FEV1, decrease of day and night dyspnea attacks, quantity of exacerbations, increase of total point of АСТтм test. Despite the larger value of coefficient of expensive efficiency at patients of the 1st group in comparison with the 2nd group, it is necessary to consider that the allergen immunotherapy interferes the progressing of the disease that will compensate the cost of this method of treatment in the future.

Conclusion. We received the results that showed the efficiency of the timely done allergen immunotherapy at patients with the mild and moderate allergic bronchial asthma, and is able tto reduce financial expenses considerably.

1. Belousov D.Yu., Afanas'eva E.V., Efremova E.A. Kachestvennaya klinicheskaya praktika. 2013; 1: 27-43.

2. Gorbovskoi F.V., Vorzheva I.I., Buinova S.N. Sib. med. zhurn. 2012; 114 (7): 29-33.

3. Goryachkina L.A., Nenasheva N.M. Lechashchii vrach. 2008; 5: 9-10.

4. Goryachkina L.A, Peredkova E.V., Astaf'eva N.G. Pollinozy. Pollinosis. Clinical Allergy and Immunology. A guide for practitioners. Ed. LA Goryachkina, KP Kashkina [Klinicheskaya allergologiya i immunologiya. Rukovodstvo dlya praktikuyushchikh vrachei. Pod red. L.A. Goryachkinoi, K.P. Kashkina (in Russian)]. Moscow. 2009; 351-362.

5. Gushchin I.S., Kurbacheva O.M. Allergy and allergen-specific immunotherapy. Allergies [Allergiya i allergen-spetsificheskaya immunoterapiya. Allergiya (in Russian)]. Moscow. 2010; 228 s.

6. Demko I.V. Asthma: Questions of diagnostics, treatment, socioeconomic aspects [Bronkhial'naya astma: voprosy diagnostiki, lecheniya, sotsial'no-ekonomicheskie aspekty (in Russian)]. Krasnoyarsk. 2006; 218 s.

7. Demko I.V., Tolkushin A.G., Kozlov S.N. i dr. Pul'monologiya. 2008; 4: 56-59.

8. Merkulova I.Yu., Zhestkov A.V. Vestnik sovremennoi klinicheskoi meditsiny. 2014; 7 (1): 123-125.

9. Sobko E.A., Demko I.V., Solov'eva I.A. i dr. Sibirskoe meditsinskoe obozrenie. 2015; 1: 84-90.

10. Standardization of pulmonary function tests. The official report of the European Respiratory Society. Pulmonology [Standartizatsiya legochnykh funktsional'nykh testov. Ofitsial'nyi otchet Evropeiskogo respiratornogo obshchestva. Pul'monologiya (in Russian)]. 1993; 6-44.

11. Federal guidelines for the conduct of allergen-specific immunotherapy: Raak approved by the Presidium of December 23, 2013. [Electronic resource]. Russian Association of Allergology and Clinical Immunology http://www.raaci.ru/ClinRec/7.ASIT.pdf. [Federal'nye klinicheskie rekomendatsii po provedeniyu allergen-spetsificheskoi immunoterapii: utverzhdeno Prezidiumom RAAKI 23 dekabrya 2013 g. Rossiiskaya assotsiatsiya allergologov i klinicheskikh immunologov (in Russian)]. Moscow. 2013 (accessed 20.03.2015).

12. Chernyak B.A., Vorzheva I.I. Prakticheskaya meditsina. 2009; 35: 55-58.

13. Chuchalin A.G. Global strategy for the treatment and prevention of asthma [Global'naya strategiya lecheniya i profilaktiki bronkhial'noi astmy (in Russian)]. Moscow. 2007; 104 s.

14. Yagudina R.I., Kulikov A.Yu., Krysanov I.S., Litvinenko M.M., Morozov A.L. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology. 2009; 1: 3-6.

15. Yagudina R.I., Kulikov A.Yu., Metelkin I.A. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology.2012; 4 (5): 3-8.

16. Fedoseyeva V.N. Creation of the allergovaccines on the base of new technologies. Russian Allergological Journal. 2009; 1: 10-17.

17. Global Initiative for Asthma. Global strategy for asthma management andprevention. Updated 2012 [Electronic resource]. ginasthma.org. URL: http://www.ginasthma.org/local/uploads/files/GINA_Report_March13.pdf] (accessed 20.03.2015).

18. Hankin C.S., Cox L. Allergy immunotherapy: what is the evidence for cost saving? Curr Opin Allergy Clin Immunol. 2014; 14 (4): 363-370.

19. Kurbacheva O.M., Pavlov K.S. Allergen immunotherapy. Doctor. Ru. 2010; 2 (52): 16-19.

20. Nathan R.A., Sorkness C.A., Kosinski M. et al. Development of the asthma control test: a survey for assessing asthma control. J. Allergy Clin. Immunol. 2004; 113 (1): 59-65.